Labiotech.eu

News and Trends 26 Feb 2016

Biotech of the week: Kallistem, producing Functional In vitro Spermatozoids in France

This week, we leave Lisbon, Portugal and head up to Lyon, the so-called gastronomical capital of France. Besides bird watching, a beautiful cathedral and a multi-purpose Roman amphitheatre, and of course delicious food, Lyon is where Kallistem, our Biotech of the Week, is located. City: Lyon, France Founded: 2012 Employees: 7 (as of 02/2016) Financial Data: N/A CEO: […]

February 26, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 25 Feb 2016

NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious)

NGS-Giant Illumina (US) is suing Oxford Nanopore (UK), the Unicorn ready to disrupt gene sequencing. What’s the story? Illumina currently has the monopoly on NGS equipment, and Illumina’s machines make a common (and bulky) fixture in labs all over the world. In the future, many hospitals will move into data-driven medicine and NGS plays an important […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

nestle health sciences pronutria investment amino acids food

News and Trends 25 Feb 2016

Boston Food Biotech Gets €38M from Nestlé

Pronutria (US) is a start-up out of Flagship Ventures developing nutritional therapies which has now gotten a huge equity investment from Nestlé Health Science (Switzerland). Pronutria is a cool Biotech start-up taking an innovative approach to treat diseases caused by amino acid imbalance, such as muscle loss, and neurological and liver complications. Besides being essential for protein synthesis, […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 25 Feb 2016

High Quality Grade plasmids for a better gene therapy

Quality of RNA and viral vectors used in clinical trials is subject to strict regulation. Plasmids that are needed for production of these complex molecules are also on authorities’ radar. German-based biotech PlasmidFactory, delivers the right solution with its High Quality Grade plasmids. For decades, artificially constructed plasmids have been used as vectors in genetic […]

February 25, 2016 - 4 minutesmins - By Joachim Eeckhout

News and Trends 24 Feb 2016

German Biotech wins FDA Approval for New Liver Cancer Trial

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

microbiome lyon czech mouse igf1 growth research

News and Trends 24 Feb 2016

Your Microbiome even Impacts how Tall you are!

Research at the University of Lyon (France) and Czech Academy of Sciences have found a previously unknown link between the microbiome and Human growth, as well as a potential therapeutic application for Lactobacillus plantarum. The microbiome is a hot field for research and Health Biotechs alike, and Europe is home to some of the leaders in […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

aspergillosis aspergillus mathias eu pet mri

News and Trends 23 Feb 2016

This new Antibody-based Imaging Technology could help fight Deadly Fungal Infections

It is estimated that up to 200,000 people globally die from fungal lung infections (Aspergillosis). Now, the EU-funded Fp7 MATHIAS project has developed an imaging technique to help doctors fight this huge killer of patients with weakened immune systems. The new test involves attaching radioactively labelled antibodies to the infecting structures formed by the fungus Aspergillus fumigatus. These fungal spores […]

February 23, 2016 - 3 minutesmins - By Dani Bancroft

gilead hiv aids grant retroviral truvada

News and Trends 23 Feb 2016

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years. Targets are academic institutions and non-profit organization. HIV remains a global health challenge, with around 37 million people infected in the world. The rate of new infections fell in the last decades, but it is […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

desktop genetics gene ngs illumina epigenetics

News and Trends 23 Feb 2016

UK Start-Up Gets €380k to Understand Cancer with CRISPR

Desktop Genetics, a small bioinformatics start-up out of London, has won a substantial grant to understand why some cancer cells just won’t quit. To do this, it relies on CRISPR, their expertise with genetic data, and research from Imperial College London. Desktop Genetics has already proven that it can move some money, with a €1.87 […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock exchange in the world, based in New York, and the largest for high-tech companies. It seems to be the real test for a European biotech to […]

February 23, 2016 - 6 minutesmins - By Philip Hemme

paion surgery Remimazolam cardiac colonoscopy praion

News and Trends 22 Feb 2016

This German Biotech had to stop its EU Phase III Trial for Lack of Recruitment

The Aachen-based pharma Paion (Germany), has been forced to axe a European phase III trial for a Surgical sedative, after failing to recruit enough patients. The company will instead focus its efforts on its ongoing US trials. This is a blow to Paion’s pipeline, which is led by Remimazolam. The company stock price decreased almost 40%, but it […]

February 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

osteoporosis vertebral column denosumab amgen ucb

News and Trends 22 Feb 2016

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects. UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an […]

February 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biotech of the week: Kallistem, producing Functional In vitro Spermatozoids in France

NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious)

Boston Food Biotech Gets €38M from Nestlé

High Quality Grade plasmids for a better gene therapy

German Biotech wins FDA Approval for New Liver Cancer Trial

Your Microbiome even Impacts how Tall you are!

This new Antibody-based Imaging Technology could help fight Deadly Fungal Infections

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

UK Start-Up Gets €380k to Understand Cancer with CRISPR

7 Trendy European Biotechs Listed on the NASDAQ in 2016

This German Biotech had to stop its EU Phase III Trial for Lack of Recruitment

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

Subscribe to our newsletter to get the latest biotech news!